Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Medical Decision Making
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kuntz, K. M.
Right arrow Articles by Weinstein, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuntz, K. M.
Right arrow Articles by Weinstein, M. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Life Expectancy Biases in Clinical Decision Modeling

Karen M. Kuntz, ScD

Milton C. Weinstein, PhD

Clinical decision models often rely upon survival models predicated on disease-specific hazard functions combined with baseline hazard functions obtained from standard life tables. Two biases may arise in such a modeling process. First, life expectancy estimates may be biased even if estimates of survival probabilities are unbiased (misestimation bias). In sim ulation studies, the authors discovered that the magnitude of misestimation bias is larger as life expectancy increases, sample size decreases, and censoring percentage increases. In the context of a simple decision analysis, they found that imbalances in the sample sizes for the data used to estimate the parameters among different strategies resulted in non- optimal decisions in the long run. The second bias stems from misspecification of the survival model itself (misspecification bias). Using a simple cost-effectiveness model, the authors found that life expectancies and incremental cost-effectiveness ratios differed depending on whether an excess-mortality or a proportional-hazards model was specified. In addition, a predictable pattern was observed for these two survival models when extrapolated to other age and gender groups. Key words: Markov models; Markov-cycle tree; decision making; excess-mortality model; proportional-hazards model; life expectancy. (Med Decis Making 1995;15:158-169)

Medical Decision Making, Vol. 15, No. 2, 158-169 (1995)
DOI: 10.1177/0272989X9501500209
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 QJMHome page
J. Benbassat and R. Baumal
The time horizons of formal decision analyses
QJM, June 1, 2007; 100(6): 383 - 388.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. S. Chan, B. K. Nallamothu, H. S. Gurm, R. A. Hayward, and S. Vijan
Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease
Circulation, May 8, 2007; 115(18): 2398 - 2409.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
S. K. Plevritis
Decision Analysis and Simulation Modeling for Evaluating Diagnostic Tests on the Basis of Patient Outcomes
Am. J. Roentgenol., September 1, 2005; 185(3): 581 - 590.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
A. B. Rosen, M. B. Hamel, M. C. Weinstein, D. M. Cutler, A. M. Fendrick, and S. Vijan
Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes
Ann Intern Med, July 19, 2005; 143(2): 89 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
N. F. Col, G. Weber, A. Stiggelbout, J. Chuo, R. D'Agostino, and P. Corso
Short-term Menopausal Hormone Therapy for Symptom Relief: An Updated Decision Model
Arch Intern Med, August 9, 2004; 164(15): 1634 - 1640.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
K. M. Kuntz and S. J. Goldie
Assessing the Sensitivity of Decision-Analytic Results to Unobserved Markers of Risk: Defining the Effects of Heterogeneity Bias
Med Decis Making, June 1, 2002; 22(3): 218 - 227.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
N. J.O. Birkmeyer
Simulation techniques to support prosthetic valve choice in aortic valve replacement: Reply
Ann. Thorac. Surg., November 1, 2001; 72(5): 1795 - 1796.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. A. Ganz, K. M. Kuntz, G. A. Jacobson, and J. Avorn
Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction
Ann Intern Med, May 16, 2000; 132(10): 780 - 787.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
R. R. Holland, C. A. Ellis, B. M. Geller, D. A. Plante, and R. H. Secker-Walker
Life Expectancy Estimation with Breast Cancer: Bias of the Declining Exponential Function and an Alternative to Its Use
Med Decis Making, October 1, 1999; 19(4): 385 - 393.
[Abstract] [PDF]

Home page
 JAMAHome page
N. F. Col, M. H. Eckman, R. H. Karas, S. G. Pauker, R. J. Goldberg, E. M. Ross, R. K. Orr, and J. B. Wong
Patient-Specific Decisions About Hormone Replacement Therapy in Postmenopausal Women
JAMA, April 9, 1997; 277(14): 1140 - 1147.
[Abstract] [PDF]